Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

129.42USD
15 Feb 2019
Change (% chg)

$3.49 (+2.77%)
Prev Close
$125.93
Open
$127.19
Day's High
$129.46
Day's Low
$126.19
Volume
593,648
Avg. Vol
639,239
52-wk High
$140.76
52-wk Low
$92.57

Latest Key Developments (Source: Significant Developments)

Temasek Holdings Cuts Share Stake In Amazon.Com, Takes in Total SA
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN AMAZON.COM BY 46.6 PERCENT TO 35,153 SHARES- SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE IN TOTAL SA OF 460,885 SPONSORED ADR.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALEXION PHARMACEUTICALS INC BY 49.7 PERCENT TO 616,630 SHARES.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF DECEMBER 31, 2018 AND COMPARED WITH PREVIOUS QUARTER ENDED AS OF SEPTEMBER 30, 2018.  Full Article

Alexion Reports Fourth Quarter And Full Year 2018 Results
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $2.14.Q4 GAAP LOSS PER SHARE $0.20.Q4 REVENUE $1.129 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.06 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.82 -- REFINITIV IBES DATA.SEES FY 2019 GAAP EARNINGS PER SHARE $6.14 TO $7.26.SEES FY 2019 REVENUE $4.625 BILLION TO $4.7 BILLION.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $9.10 TO $9.30.ALEXION PHARMACEUTICALS - FILED U.S. & EU SUBMISSIONS FOR SOLIRIS IN NEUROMYELITIS OPTICA SPECTRUM DISORDER & ON TRACK TO FILE IN JAPAN LATER IN 2019.FY2019 EARNINGS PER SHARE VIEW $8.73, REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA.SEES 2019 TOTAL REVENUES $4,625 TO $4,700 MILLION.SEES 2019 SOLIRIS/ULTOMIRIS REVENUES $3,970 TO $4,020 MILLION.FY2019 REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA.  Full Article

Fortress Biotech Announces CAEL-101 Strategic Partnership With Alexion Pharmaceuticals
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH ANNOUNCES CAEL-101 STRATEGIC PARTNERSHIP WITH ALEXION PHARMACEUTICALS.FORTRESS BIOTECH INC - FORTRESS-FOUNDED CAELUM BIOSCIENCES TO RECEIVE $60 MILLION IN A STRATEGIC EQUITY INVESTMENT AND OPTION FEE.FORTRESS BIOTECH INC - ALEXION HAS OPTION TO ACQUIRE CAELUM BIOSCIENCES BASED ON PHASE 2 DATA.FORTRESS BIOTECH - UNDER TERMS ALEXION WILL ACQUIRE A MINORITY EQUITY INTEREST IN CAELUM AND AN EXCLUSIVE OPTION TO ACQUIRE REMAINING EQUITY IN CO.FORTRESS BIOTECH INC - COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS OF UP TO $500 MILLION IN EVENT ALEXION EXERCISES ACQUISITION OPTION.FORTRESS BIOTECH INC - ALEXION AND CAELUM WILL COLLABORATE ON DESIGN OF ONGOING DEVELOPMENT PROGRAM FOR CAEL-101.  Full Article

Alexion, Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain Amyloidosis
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND CAELUM BIOSCIENCES ANNOUNCE COLLABORATION TO DEVELOP TARGETED THERAPY FOR LIGHT CHAIN (AL) AMYLOIDOSIS.UNDER TERMS OF AGREEMENT, ALEXION WILL ACQUIRE A MINORITY EQUITY INTEREST IN CAELUM.CAELUM TO RECEIVE UP TO $60 MILLION FOR EQUITY INVESTMENT AND OPTION FEE.ALEXION HAS OPTION TO ACQUIRE CAELUM BASED ON PHASE 2 DATA.COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS OF UP TO $500 MILLION.ALEXION PHARMACEUTICALS-WILL MAKE PAYMENTS TO CAELUM TOTALING UP TO $60 MILLION, INCLUDING PURCHASE PRICE FOR EQUITY, DEVELOPMENT FUNDING PAYMENTS.CAELUM WILL BE RESPONSIBLE FOR CONDUCTING DEVELOPMENT PROGRAM THROUGH END OF PHASE 2 AND FOR MANUFACTURING CAEL-101.ALEXION AND CAELUM WILL COLLABORATE ON DESIGN OF ONGOING DEVELOPMENT PROGRAM FOR CAEL-101.  Full Article

Alexion Announces Positive Top-Line Results From Phase 3 Study Of Ultomiris
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ULTOMIRIS™ (RAVULIZUMAB-CWVZ) IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS INC - STUDY MET PRIMARY OBJECTIVE OF COMPLETE THROMBOTIC MICROANGIOPATHY (TMA) RESPONSE.ALEXION PHARMACEUTICALS INC - REGULATORY SUBMISSION IN U.S. PLANNED FOR FIRST HALF OF 2019, FOLLOWED BY EUROPEAN UNION AND JAPAN.ALEXION PHARMACEUTICALS - IN CRITICALLY ILL PATIENTS, THERE WERE 4 PATIENT DEATHS, NONE OF WHICH CONSIDERED RELATED TO TREATMENT WITH ULTOMIRIS.  Full Article

Alexion Receives Early FDA Approval For Ultomiris In Adults With Paroxysmal Nocturnal Hemoglobinuria
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION RECEIVES EARLY FDA APPROVAL FOR ULTOMIRIS™ (RAVULIZUMAB-CWVZ) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMA - REGULATORY AUTHORITIES IN EU, JAPAN HAVE ACCEPTED & ARE REVIEWING APPLICATIONS FOR ULTOMIRIS APPROVAL AS TREATMENT FOR ADULTS WITH PNH.  Full Article

FDA Releases Label On Its Website For Alexion Pharmaceuticals' Ultomiris
Friday, 21 Dec 2018 

Dec 21 (Reuters) - U.S. Food and Drug Administration::U.S. FDA RELEASES LABEL ON ITS WEBSITE FOR ALEXION PHARMACEUTICALS' ULTOMIRIS.U.S. FDA - ULTOMIRIS IS A COMPLEMENT INHIBITOR INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.U.S. FDA - WARNS THAT LIFE-THREATENING MENINGOCOCCAL INFECTIONS HAVE OCCURRED IN PATIENTS TREATED WITH ULTOMIRIS.  Full Article

Alexion Pharmaceuticals Wins FDA Approval For Ultomiris - FDA Website
Friday, 21 Dec 2018 

Dec 21 (Reuters) - U.S. Food and Drug Administration::ALEXION PHARMACEUTICALS WINS FDA APPROVAL FOR ULTOMIRIS - FDA WEBSITE.  Full Article

Dicerna Pharmaceuticals Inc Says Alexion May Terminate Collaboration Agreement At Any Time Without Cause
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC - ALEXION MAY TERMINATE COLLABORATION AGREEMENT AT ANY TIME WITHOUT CAUSE FOLLOWING A 90-DAY NOTICE PERIOD.DICERNA PHARMACEUTICALS-ALEXION COLLABORATION AGREEMENT ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS TO COMPANY OF UP TO $600.0 MILLION.  Full Article

Alexion To Acquire Syntimmune
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION TO ACQUIRE SYNTIMMUNE.ALEXION PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALEXION WILL ACQUIRE SYNTIMMUNE FOR AN UPFRONT PAYMENT OF $400 MILLION.ALEXION PHARMACEUTICALS INC - ALEXION INTENDS TO FINANCE ACQUISITION THROUGH CASH ON HAND..ALEXION PHARMACEUTICALS INC - ALEXION INTENDS TO FINANCE ACQUISITION THROUGH CASH ON HAND.ALEXION PHARMACEUTICALS INC - DEAL FOR TOTAL VALUE OF UP TO $1.2 BILLION.ALEXION PHARMACEUTICALS INC - ALEXION WILL ACQUIRE SYNTIMMUNE, WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT PAYMENTS OF UP TO $800 MILLION.  Full Article

Factbox: Bristol-Myers' $74 billion Celgene buy has investors looking for next deal

Bristol-Myers Squibb Co's announcement that it would buy Celgene Corp for $74 billion (59 billion pounds) has raised investors' hopes that a wave of consolidation among drugmakers could be coming. The following are some of the companies in the sector whose shares rose on Thursday on takeover speculation following the deal announcement: